Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

NCT04913571 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

265

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Eribulin
DRUG: Tislelizumab

Sponsor

Fudan University